ArticleInfection2022
Longitudinal prediction of hospital-acquired acute kidney injury in COVID-19: a two-center study.
Article in Infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cardiac Magnetic Resonance Imaging of COVID-19-Associated Cardiac Sequelae: A Systematic Review.Reviews in cardiovascular medicine · 2022Pooled it
- Elevated risk of first-time pulmonary hypertension among COVID-19 survivors: a 4.5-year longitudinal study.ERJ open research · 2026Article
- COVID-19 and cardiovascular outcomes in patients with pre-existing hypertension.Journal of human hypertension · 2026Review
- Real-world clinical outcomes of CAR-T therapy from the Montefiore health system in the Bronx.Annals of hematology · 2025Article
- Elevated Risk of Long-Term Decline in Left Ventricular Ejection Fraction After COVID-19.Journal of the American Heart Association · 2025Article
- Lactate/albumin ratio predicts mortality in critically ill COVID-19 patients: a retrospective machine learning study.Scientific reports · 2025Article
- Incidence of Anxiety Diagnosis up to Four Years Post SARS-CoV-2 Infection in the Montefiore Medical Center in the Bronx and New York.Diagnostics (Basel, Switzerland) · 2025Article
- Systematic Review and Meta-Analysis of Machine Learning Models for Acute Kidney Injury Risk Classification.Journal of the American Society of Nephrology : JASN · 2025Article
- Elevated risk of new-onset chronic fatigue syndrome/myalgic encephalomyelitis up to four years after SARS-CoV-2 infection.Journal of translational medicine · 2025Article
- Incidence and risk factors of new clinical disorders in patients with COVID-19 hyperinflammatory syndrome.Scientific reports · 2025Article
- Long-term outcomes of patients with pre-existing coronary artery disease after SARS-CoV-2 infection.EBioMedicine · 2025Article
- New-onset conjunctivitis 3.5 years post SARS-CoV-2 infection in an inner-city population in the Bronx.BMJ open ophthalmology · 2025Article
- Impact of COVID-19 on long-term outcomes in Parkinson's disease.European journal of neurology · 2025Article
- Long term outcomes of patients with chronic kidney disease after COVID-19 in an urban population in the Bronx.Scientific reports · 2025Article
- Patients With Type 2 Diabetes Are at Greater Risk of Developing New Hypertension and Chronic Kidney Disease Following COVID-19.Journal of diabetes research · 2025Article
- New-onset gastrointestinal disorders in COVID-19 patients 3.5 years post-infection in the inner-city population in the Bronx.Scientific reports · 2024Article
- New-onset cardiovascular diseases post SARS-CoV-2 infection in an urban population in the Bronx.Scientific reports · 2024Article
- Long-Term Outcomes of Patients with Pre-Existing Essential Tremor After SARS-CoV-2 Infection.Diagnostics (Basel, Switzerland) · 2024Article
- Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment.PLoS medicine · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the temporal characteristics of clinical variables of hospital-acquired acute kidney injury (AKI) in COVID-19 patients and to longitudinally predict AKI onset.
methodsThere were 308 hospital-acquired AKI and 721 non-AKI (NAKI) COVID-19 patients from Stony Brook Hospital (New York, USA) data, and 72 hospital-acquired AKI and 303 NAKI COVID-19 patients from Tongji Hospital (Wuhan, China). Demographic, comorbidities, and longitudinal (3 days before and 3 days after AKI onset) clinical variables were used to compute odds ratios for and longitudinally predict hospital-acquired AKI onset.
resultsCOVID-19 patients with AKI were more likely to die than NAKI patients (31.5% vs 6.9%, adjusted p < 0.001, OR = 4.67 [95% CI 3.1, 7.0], Stony Brook data). AKI developed on average 3.3 days after hospitalization. Procalcitonin was elevated prior to AKI onset (p < 0.05), peaked, and remained elevated (p < 0.05). Alanine aminotransferase, aspartate transaminase, ferritin, and lactate dehydrogenase peaked the same time as creatinine, whereas D-dimer and brain natriuretic peptide peaked a day later. C-reactive protein, white blood cell and lymphocyte showed group differences - 2 days prior (p < 0.05). Top predictors were creatinine, procalcitonin, white blood cells, lactate dehydrogenase, and lymphocytes. They predicted AKI onset with areas under curves (AUCs) of 0.78, 0.66, and 0.56 at 0, - 1, and - 2 days prior, respectively. When tested on the Tongji Hospital data, the AUCs were 0.80, 0.79, and 0.77, respectively.
conclusionsTime-locked longitudinal data provide insight into AKI progression. Commonly clinical variables reasonably predict AKI onset a few days prior. This work may lead to earlier recognition of AKI and treatment to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.